Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 39

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Myeloproliferative neoplasm

Recruiting

Study on the Effects of Atorvastatin for Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Sjaelland

Plasma cell myeloma

Recruiting

Study on Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for Patients with Multiple Myeloma and Acute Kidney Failure

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Medizinische Universitaet Innsbruck

Plasma cell myeloma

Not yet recruiting

Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Paroxysmal nocturnal haemoglobinuria+1

Not yet recruiting

Long‑Term Safety and Tolerability of Oral Iptacopan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria or IgA Nephropathy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Diffuse large B-cell lymphoma+5

Not yet recruiting

Study of MDX2003 in Adults with Relapsed or Refractory B‑Cell Malignancies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Anaemia

Not yet recruiting

Effect of mitapivat versus placebo on transfusion burden in patients with sickle cell disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Hodgkin's disease

Not yet recruiting

Phase II Study of Brentuximab Vedotin with Drug Combination in HIV‑Positive Patients with Advanced‑Stage Classic Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

B-cell type acute leukaemia

Not yet recruiting

Phase II study of inotuzumab ozogamicin to prevent relapse in adult high‑risk acute lymphoblastic leukaemia patients after allogeneic stem cell transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Inotuzumab Ozogamicin
  • Sponsor:Fundacion PETHEMA

Chronic lymphocytic leukaemia+2

Not yet recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.